Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma

FASEB Journal

Volumn 20, Issue 10, 2006, Pages

  Tentori, Lucio ^a   Leonetti, Carlo ^b   Scarsella, Marco ^b   Muzi, Alessia ^a   Mazzon, Emanuela ^c   Vergati, Matteo ^a   Forini, Olindo ^a   Lapidus, Rena ^d   Xu, Weizheng ^d   Dorio, Annalisa Susanna ^a   Zhang, Jie ^d   Cuzzocrea, Salvatore ^c   Graziani, Grazia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d MGI Pharma   (United States)

Author keywords

Cancer; Chemotherapy; Diarrhea; Mucositis

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIBODY; GPI 15427; IRINOTECAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; POLY(ADP RIBOSE) ANTIBODY; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DACARBAZINE; DNA TOPOISOMERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; ORGANIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CELL; CANCER INHIBITION; CELL DEATH; CELL PROLIFERATION; CHEMOSENSITIVITY; COLON CANCER; COLONY FORMATION; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INHIBITION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINE INJURY; JEJUNUM DAMAGE; JEJUNUM DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT; CHEMICALLY INDUCED DISORDER; CLONOGENIC ASSAY; COLON TUMOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENTEROPATHY; PATHOLOGY; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL PROLIFERATION; COLONIC NEOPLASMS; COLONY-FORMING UNITS ASSAY; DACARBAZINE; DIARRHEA; DNA TOPOISOMERASES, TYPE I; DRUG SYNERGISM; ENZYME INHIBITORS; INTESTINAL DISEASES; ORGANIC CHEMICALS; POLY(ADP-RIBOSE) POLYMERASES; TUMOR BURDEN;

EID: 33845672155     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.06-5916fje     Document Type: Article

References (48)

1. Douillard, J. Y., Cunningham, D., Roth, A. D., Navarro, M., James, R. D., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041-1047
2. Rasheed, Z. A., and Rubin, E. H. (2003) Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22, 7296-7304
3. 6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin. Cancer Res. 6, 4110-4118
4. Patel, V. J., Elion, G. B., Houghton, P. J., Keir, S., Pegg, A. E., Johnson, S. P., Dolan, M. E., Bigner, D. D., and Friedman, H. S. (2000) Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. Clin. Cancer Res. 6, 4154-4157
5. Jones, S. F., Gian, V. G., Greco, F. A., Miranda, F. T., Shipley, D. L., Thompson, D. S., Hainsworth, J. D., Toomey, M. A., Willcutt, N. T., and Burris, H. A., 3rd. (2003) Trial of irinotecan and temozolomide in patients with solid tumors. Oncology 17, 41-45
6. Wagner, L. M., Crews, K. R., Iacono, L. C., Houghton, P. J., Fuller, C. E., McCarville, M. B., Goldsby, R. E., Albritton, K., Stewart, C. F., and Santana, V. M. (2004) Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin. Cancer Res. 10, 840-848
7. Reardon, D. A., Quinn, J. A., Rich, N. J., Desjardins, A., Vredenburgh, J., Gururangan, S., Sathornsumetee, S., Badruddoja, M., McLendon, R., Provenzale, J., et al. (2005) Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104, 1478-1486
8. Tentori, L., and Graziani, G. (2004) Temozolomide: an update on pharmacological strategies to increase its antitumor activity. Med. Chem. Rev.-Online. 1, 144-150
9. D'Atri, S., Tentori, L., Lacal, P. M., Graziani, G., Pagani, E., Benincasa, E., Zambruno, G., Bonmassar, E., and Jiricny, J. (1998) Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharmacol. 54, 334-341
10. Jacob, S., Aguado, M., Fallik, D., and Praz, F. (2001) The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res. 61, 6555-6562
11. Magrini, R., Bhonde, M. R., Hanski, M. L., Notter, M., Scherubl, H., Boland, C. R., Zeitz, M., and Hanski, C. (2002) Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int. J. Cancer 101, 23-31
12. Tentori, L., Leonetti, C., Scarsella, M., d'Amati, G., Portarena, I., Zupi, G., Bonmassar, E., and Graziani, G. (2002) Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood 99, 2241-2244
13. Tentori, L., Leonetti, C., Scarsella, M., D'Amati, G., Vergati, M., Portarena, I., Xu, W., Kalish, V., Zupi, G., Zhang, J., and Graziani, G. (2003) Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma. Clin. Cancer Res. 9, 5370-5379
14. Miknyoczki, S. J., Jones-Bolin, S., Pritchard, S., Hunter, K., Zhao, H., Wan, W., Ator, M., Bihovsky, R., Hudkins, R., Chatterjee, S., et al. (2003) Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther. 2, 371-382
15. Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG 14361. J. Natl. Cancer Inst. 96, 56-67
16. Tentori, L., Leonetti, C., Scarsella, M., Vergati, M., Xu, W., Calvin, D., Morgan, L., Tang, Z., Woznizk, K., Alemu, C., et al. (2005) Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. Int. J. Oncol. 26, 415-422
17. Schreiber, V., Ame, J. C., Dolle, P., Schultz, I., Rinaldi, B., Fraulob, V., Menissier-de Murcia, J., and de Murcia, G. (2002) Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J. Biol. Chem. 277, 23028-23036
18. Yung, T. M., Sato, S., and Satoh, M. S. (2004) Poly(ADPribosyl) ation as a DNA damage-induced post-translational modification regulating poly(ADP-ribose) polymerase-1 topoisomerase I interaction. J. Biol. Chem. 279, 39686-39696
19. Malanga, M., and Althaus, F. R. (2004) Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing. J. Biol. Chem. 279, 5244-5248
20. Tentori, L., and Graziani, G. (2005) Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol. Res. 52, 25-33
21. Ha, H. C., and Snyder, S. H. (1999) Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc. Natl. Acad. Sci. U. S. A. 96, 13978-13982
22. Tentori, L., Vergati, M., Muzi, A., Levati, L., Ruffini, F., Forini, O., Vernole, P., Lacal, P. M., and Graziani, G. (2005) Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. Int. J. Oncol. 27, 525-535
23. Bakondi, E., Bai, P., Szabo, E. E., Hunyadi, J., Gergely, P., Szabo, C., and Virag, L. (2002) Detection of poly(ADP-ribose) polymerase activation in oxidatively stressed cells and tissues using biotinylated NAD substrate. J. Histochem. Cytochem. 50, 91-98
24. Fittkau, M., Voigt, W., Holzhausen., H. J., and Schmoll, H. J. (2004) Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats. J. Cancer Res. Clin. Oncol. 130, 388-394
25. Cuzzocrea, S., Misko, T. P., Costantino, G., Mazzon, E., Micali, A., Caputi A. P., Macarthur, H., and Salvemini, D. (2000) Beneficial effects of peroxynitrite decomposition catalyst in a rat model of splanchnic artery occlusion and reperfusion. FASEB J. 14, 1061-1072
26. Rajendra, R., Gounder, M. K., Saleem, A., Schellens, J. H., Ross, D. D., Bates, S. E., Sinko, P., and Rubin, E. H. (2003) Differential effects of the breast cancer resistance protein on the cellular accumulation and cytotoxicity of 9-aminocamptothecin and 9-nitrocamptothecin. Cancer Res. 63, 3228-3233
27. Rowley, P. T. Inherited susceptibility to colorectal cancer. (2005) Annu. Rev. Med. 56, 539-554
28. Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J. P., Markowitz, S., Willson, J. K., Hamilton, S. R., Kinzler, K. W., et al. (1998) Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 95, 6870-6875
29. Fedier, A., and Fink, D. (2004) Mutations in DNA mismatch repair genes: implications for DNA damage signaling and drug sensitivity. Int. J. Oncol. 24, 1039-1047
30. Engelward, B. P., Weeda, G., Wyatt, M. D., Broekhof, J. L., de Wit, J., Donker, I., Allan, J. M., Gold, B., Hoeijmakers, J. H., and Samson, L. D. (1997) Base excision repair deficient mice lacking the Aag alkyladenine DNA glycosylase. Proc. Natl. Acad. Sci. U. S. A. 94, 13087-13092
31. Roth, R. B., and Samson, L. D. (2002) 3-Methyladenine DNA glycosylase-deficient Aag null mice display unexpected bone marrow alkylation resistance. Cancer Res. 62, 656-660
32. Trivedi, R. N., Almeida, K. H., Fornsaglio, J. L., Schamus, S., and Sobol, R. W. (2005) The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res. 65, 6394-6400
33. Doyle, L. A., and Ross, D. D. (2003) Multidrug resistance mediated by the breast cancer resistance protein breast cancer resistance protein (ABCG2). Oncogene 22, 7340-7358
34. Idogawa, M., Yamada, T., Honda, K., Sato, S., Imai, K., and Hirohashi, S. (2005) Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex. Gastroenterology 128, 1919-1936
35. Fogh, J., and Trempe, G. (1975) New human tumour cell lines. In Human tumour cells in vitro (Fogh, J., ed) pp. 115-141, Plenum Press, New York, U. S. A.
36. Wedge, S. R., Porteus, J. K., May, B. L., and Newlands, E. S. (1996) Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro. Br. J. Cancer 73, 482-490
37. 6-methylguanine. Cancer Res. 61, 53-58
38. Saliba, F., Hagipantelli, R., Misset, J. L., Bastian, G., Vassal, G., Bonnay, M., Herait, P., Cote, C., Mahjoubi, M., Mignard, D., and Cvitkovic, E. (1998) Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment. J. Clin. Oncol. 16, 2745-2751
39. Benson, A. B., 3rd, Ajani, J. A., Catalano, R. B., Engelking, C., Kornblau, S. M., Martenson, J. A., Jr., McCallum, R., Mitchell, E. P., O'Dorisio, T. M., Vokes, E. E., and Wadler, S. (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J. Clin. Oncol. 22, 2918-2926
40. Mazzon, E., Dugo, L., Li, J. H., Di Paola, R., Genovese, T., Caputi, A. P., Zhang, J., and Cuzzocrea, S. (2002) GPI 6150, a PARP inhibitor, reduces the colon injury caused by dinitrobenzene sulfonic acid in the rat. Biochem. Pharmacol. 64, 327-337
41. Cuzzocrea, S. (2005) Shock, inflammation and PARP. Pharmacol. Res. 52, 72-82
42. Quinn, J. A., Desjardins, A., Weingart, J., Brem, H., Dolan, M. E., Delaney, S. M., Vredenburgh, J., Rich, J., Friedman, A. H., Reardon, D. A., et al. (2005) Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. 23, 7178-7187
43. Xu-Welliver, M., and Pegg, A. E. (2002) Degradation of the alkylated form of the DNA repair protein, O(6)-alkylguanine-DNA alkyltransferase. Carcinogenesis 23, 823-830
44. Umar, A., Boyer, J. C., Thomas, D. C., Nguyen, D. C., Risinger, J. I., Boyd, J., Ionov, Y., Perucho, M., and Kunkel, T. A. (1994) Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J. Biol. Chem. 269, 14367-14370
45. Gibson, N. W., Hartley, J. A., Barnes, D., and Erickson, L. C. (1986) Combined effects of streptozotocin and mitozolomide against four human cell lines of the Mer+ phenotype. Cancer Res. 46, 4995-4998
46. Papadopoulos, N., Nicolaides, N. C., Liu, B., Parsons, R., Lengauer, C., Palombo, F., D'Arrigo, A., Markowitz, S., Willson, J. K., Kinzler, K. W., et al. (1995) Mutations of GTBP in genetically unstable cells. Science 268, 1915-1917
47. Papadopoulos, N., Nicoladesi, N. C., Wei, Y. F., Ruben, S. M., Carter, K. C., Rosen, C. A., Haseltine, W. A., Fleischmann, R. D., Fraser, C. M., Adams, M. D., et al. (1994) Mutation of a MutL homolog in hereditary colon cancer. Science 263, 1625-1629
48. Koi, M., Umar, A., Chaulan, D. P., Cherian, S. P., Carethers, J. M., Kunkel, T. A., and Boland, C. R. (1994) Human chromosome 3 corrects mismatch deficiency and microsatellite instability and reduces N-methyl-N -nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 54, 4308-4312